LIBRELA
(NEW) monoclonal Arthritis Injectable Therapy
From Dr. Wheelock:
NEXT GENERATION ARTHRITIS MEDICATION
Librela has been on the market in Europe for over 2 years with pretty astounding results. Librela has just been approved for use in the U.S. May 2023.
Zoetis' early release program gave Dilworth Animal Hospital access to Librela 6-8 weeks ahead of the general public. We have been quite impressed with some of our patients' results!
If you are interested in more information or would like to start treatment please contact us. This medication is appropriate for moderate to severe CHRONIC arthritis dogs. (Dogs generally on chronic dosing of NSAIDs like Rimadyl, Galliprant, Previcoxx, Metacam, etc.)
Please see website - Librelavetteam.com for information on the product and studies.
Additional notes-
1) Librela can be used in combination with other arthritis medications, but expectations would be that Librela would allow your pet to come off other medications,
2) If you could take a 10-20 second video of your dog's arthritic limitations BEFORE treatment, it would be very helpful.
FOR CATS-
SOLENSIA - monoclonal treatment is also available for arthritic cats. (Most cats over 7 years of age have some arthritic pain.) We have been treating a number of our senior cats with Solensia Injectable since it's release in early 2022. There has been a great response. This is particularly exciting as cats are limited in treatments for chronic arthritis since their metabolism prevents long term use of drugs used by dogs and humans. Our team would be happy to discuss if this monoclonal therapy is appropriate for your fuzzy feline